Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXueli JiaoQZQinglan ZhangXLXingchen Liu

Discussion

Loading...

Member takes

Overview

Analysis shows zanubrutinib achieves high efficacy in elderly and younger high-risk patients with Mantle Cell Lymphoma, suggesting improved treatment options.

Key Points

  • Zanubrutinib combined with rituximab had an overall response rate of 100.0% in elderly patients with Mantle Cell Lymphoma.
  • The study includes 22 evaluable patients, with an MRD negativity rate of 80.0% and a progression-free survival rate of 85.7%.
  • This multicenter, investigator-initiated, prospective study focused on treatment-naïve cohorts stratified by age and risk level.
  • The findings highlight the safety profile of zanubrutinib, as no severe adverse events were reported in elderly patients.

Cite This Study

Jiao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d478https://doi.org/10.1182/blood-2025-1823
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis2025
  2. 2Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  3. 3Zanubrutinib maintenance post-autologous stem cell transplantation in Mantle Cell Lymphoma: A prospective multicenter Phase II trial2025
  4. 4Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma2025 · 1 citations
  5. 5Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience2025